Read Time:30 Second
Minerva Neurosciences Inc. said Monday that it received a refusal to file letter from the Food and Drug Administration for its application for roluperidone as a treatment for patients with schizophrenia. “The company intends to request a Type A meeting and looks forward to continued discussions with the FDA,” Minerva CEO said in a news release. Minerva’s stock has soared 109.6% so far this year, while the broader S&P 500 has declined 24.8%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
0
0